CMYC-Translocation Associated with Poor Prognosis in Relapsed DLBCL

Patients with relapsed or refractory diffuse large B-cell lymphoma and CMYC oncogene translocations had poor outcomes after reinduction therapy and stem-cell transplantation.

Patients with diffuse large B-cell lymphoma (DLBCL) and translocation of the CMYC oncogene — either alone or in combination with translocated BCL2, BCL6, or both (so-called double-hit or triple-hit DLBCL) — have poor prognosis following initial therapy with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; J Clin Oncol 2010; 28:3360 and Blood 2009; 114:3533).

Now, investigators have assessed survival and response to salvage therapy in DLBCL patients with or without CMYC translocation included in the multicenter CORAL trial of R-ICE (rituximab plus ifosfamide, carboplatin, and etoposide) versus R-DHAP (rituximab plus dexamethasone, high-dose cytarabine, and cisplatin) followed by autologous stem cell transplan…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee